- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S3780
| Related Targets | PD-1/PD-L1 CXCR STING AhR CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor |
|---|---|
| Other Immunology & Inflammation related Products | Cl-amidine Tempol Anti-mouse CD8α-InVivo Tranilast Sinomenine Geniposidic acid GI254023X (GI4023) CORM-3 Bestatin (Ubenimex) Acacetin |
|
In vitro |
DMSO
: 100 mg/mL
(145.62 mM)
Water : 100 mg/mL Ethanol : 100 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 686.7 | Formula | C32H46O16 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 148244-82-0 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | COC1=C(O)C=CC(=C1)CC(COC2OC(CO)C(O)C(O)C2O)C(COC3OC(CO)C(O)C(O)C3O)CC4=CC(=C(O)C=C4)OC | ||
| In vitro |
Secoisolariciresinol diglucoside (SDG) inhibits colon cancer cell growth by inducing S-phase cell cycle arrest. SDG is effective in mitigating iron-induced cellular damage and death. SDG is capable of preventing the increase in inflammation in iron treated cells.
|
|---|---|
| In vivo |
Secoisolariciresinol diglucoside (SDG) has been shown to decrease the production of inflammatory mediators and reduce oxidative stress. Its treatment is also found to reduce the development of hypercholesterolemic atherosclerosis in rabbits fed a high cholesterol diet, and reduce the development of diabetes in rats. SDG prevents the development of hypercholesterolemic atherosclerosis, induces angiogenesis-mediated cardioprotection, and prevents the development of type 1 and type 2 diabetes. SDG may have a cardioprotective role in cardiac iron overload.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04816890 | Completed | Type 1 Diabetes Mellitus |
Adocia |
March 23 2021 | Phase 2 |
| NCT01234506 | Completed | Oxidative Stress|Inflammation|Aging|Dementia|Pain |
University of Saskatchewan|Saskatchewan Health Research Foundation |
October 2010 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.